Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapies: Safety, CMC Draft Guidances Coming From US FDA In 2018

Executive Summary

Lengthy safety registries, extensive premarket testing for replication competent retrovirus, and manufacturing submission advice likely; pending CBER documents informed by review and approval of Novartis' Kymriah, Kite's Yescarta, and Spark's Luxturna.

You may also be interested in...



Reagan-Udall Annual Meeting: 4 Takeaways From US FDA Center Directors

US FDA's center directors chime in on topics such as antimicrobial drug development and public education at the 2019 Reagan-Udall annual meeting.  

Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway

Accelerated approval would help agency monitor gene therapies for durability and off-target effects, US FDA commissioner says.

Gene Therapy Manufacturing Remains Large Hurdle For Development, US FDA's CBER Director Says

Scale-up in particular is a challenge and FDA wants to help lower the barrier, CBER Director Peter Marks tells rare disease conference.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel